Please ensure Javascript is enabled for purposes of website accessibility

Should Merck Investors Worry About This Supreme Court Decision?

By Max Macaluso - Apr 3, 2013 at 12:39PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Can the Supreme Court of India's ruling on Novartis' Gleevec also effect Merck?

The Supreme Court of India's controversial decision to deny a patent for Novartis' cancer drug Glivec has put the country's approach to intellectual property law in the spotlight. As the debate around this ruling continues, Merck (MRK -1.54%) is the latest big pharma to face patent headwinds in India. Its top-selling diabetes drug Januvia is now facing generic competition from Glenmark Pharma, and Merck is suing for patent infringement.

Is this something that investors should worry about today, or is this potentially a long-term threat that they should keep a close eye on? Health care analyst Max Macaluso discusses this case in the following video.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$92.31 (-1.54%) $-1.44

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.